Biointelect was established in 2011 by experienced and well-known industry executive Jenny Herz to provide consulting services to companies and organisations looking to commercialise new technologies.
Since then, the Company has grown rapidly and now provides a range of services in Australia and overseas to global pharmaceutical companies, start-ups, not-for-profits and government agencies.
Its clients have included some of the most recognised brands in the pharmaceutical industry.
Biointelect has expanded its service offering over time, now covering commercial strategy and resource allocation, medical affairs, market evaluation, market access and expert insight.
Managing Director Jenny Herz was joined by husband Karl earlier this year. Both have extensive experience and are well known across the pharmaceutical industry.
Before establishing Biointelect, Jenny was an industry executive serving in senior commercial and scientific affairs roles across a number of companies. She was the first Managing Director of Sanofi Pasteur Australia, holding the position for seven years, during which time she also represented the company on the Board of Medicines Australia. As a Medicines Australia Board member, she was involved in some major reform and access discussions. Jenny has also held senior roles in Europe, for Astra Zeneca and MedImmune.
Karl has also held senior roles in the pharmaceutical industry. Following his early career with Servier and Schering Plough he joined Sigma as National Sales Manager. In his most recent role before joining Biointelect to focus on Business Development, he was Sales Manager for Lupin’s Australian subsidiary Generic Health, having previously worked in senior sales and marketing effectiveness roles in Australia and overseas.
“We have worked on a range of projects in Australia and overseas since 2011,” says Jenny. “I think our extensive commercial experience, combined with our international network and knowledge of the policy environment, gives us a unique understanding of the many issues a company can face bringing products to market.”
Jenny says knowledge of the operating environment and personal experience of the challenges confronting senior industry decision-makers is what makes the Biointelect offering unique.
“Understanding the realities of the commercial and operating environment is key to being able to assess a market opportunity, address market access challenges or recommend the best organisational structure to deliver an outcome.
“We have a great international network of KOLs and industry experts to ensure our advice is based on real market insights,” she adds.
With his focus on Business Development, Karl says the personal and tailored Biointelect approach is attractive to clients.
“Clients know the level of thinking we provide,” he says. “It’s about how we work closely with our clients to develop a tailored approach to an issue or challenge. Our strategic approach to problem solving, which is based on real knowledge and experience of launching and optimising new products, can be applied to start-ups or large pharmaceutical companies, in Australia, overseas or across regions.”
Jenny and Karl thank Biointelect’s clients for their ongoing support and look forward to working with new clients as they develop their businesses.
Biointelect is currently recruiting due to the continued support from existing clients and growth from new clients.
